Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setidegrasib versus docetaxel in previously treated KRAS G12D-mutated advanced non-small cell lung cancer
jRCT2031260120Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Setidegrasib with Docetaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Aug 2026; status: recruiting.
02
Drugs
setidegrasibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031260120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260120.